Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg

Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets

Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger

FDA approves Opdivo plus Yervoy as treatment metastatic colorectal cancer

The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date

Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab

Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone

Enhertu approved in EU in post-ET breast cancer

Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease

Avantor bags awards at Asia-Pacific Biopharma Excellence Awards 2025

Awards highlight Avantor's commitment to the Biopharma industry

Emcutix and WiQo sign licensing partnership for derma-cosmetic treatments in India

PRX-PLUS has a unique product feature with its deep-impacting formula